Cent Eur J Public Health 2013, 21(4):233-236 | DOI: 10.21101/cejph.a3959

Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in Adults. Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults

Endre Ludwig1, Serhat Ünal2, Miron Bogdan3, Roman Chlíbek4, Yavor Ivanov5, Roman Kozlov6, Hartmut Lode7, Zsófia Mészner8, Roman Prymula9, Galia Rahav10, Anna Skoczyńska11, Ivan Solovič12, Abdullah Sayıner13
1 Division of Infectious Diseases, Department of Internal Medicine No. II, Semmelweis Medical University, Budapest, Hungary
2 Section of Infectious Diseases, Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey
3 Carol Davila University of Medicine, Bucharest and Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania
4 Department of Epidemiology, Faculty of Military Health Sciences, University of Defence, Hradec Králové, Czech Republic
5 Pulmonology and Phthisiatry Clinic, University Hospital, Pleven, Bulgaria
6 Institute of Antimicrobial Chemotherapy, Smolensk State Medical Academy, Smolensk, Russia
7 Research Center of Medical Studies (RCMS), Institute for Clinical Pharmacology, Charité University Medicine of Berlin, Berlin, Germany
8 National Institute of Child Health, Szent Laszlo Hospital for Infectious Diseases, Budapest, Hungary
9 University Hospital, Hradec Králové, Czech Republic
10 Infectious Disease Unit, Sheba Medical Centre, Tel Hashomer, Ramat-Gan, Israel
11 National Reference Centre for Bacterial Meningitis, Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Warsaw, Poland
12 Pulmonology Department of National Institute for TB, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Catholic University, Ružomberok, Slovakia
13 Department of Chest Diseases, Ege University Medical Faculty, Izmir, Turkey

Background: An important development in the field of adult pneumococcal vaccination since the last Consensus Statement, published by the Expert Panel of Central and Eastern Europe and Israel (the Region) in September 2012, was the licensure of the 13-valent pneumococcal conjugate vaccine (PCV13) for adults aged 50 years and older.

Discussion: The Expert Panel has developed this Position Statement as an update to its previous Consensus to address the following topics which are likely to be on the agenda of national scientific societies during the ongoing updates of vaccination recommendations in the Region: the availability of a pneumococcal conjugate vaccine for adults over 50 years of age, the available clinical evidence on its use in adults, and the future place of conjugate vaccines in adult pneumococcal vaccination. The Expert Panel concluded that there is sufficient epidemiologic immunogenicity and safety evidence to use PCV 13 in adults over 50 years of age.

Results: The use of conjugate vaccine induces immunological memory and can overcome some limitations associated with the plain polysaccharide vaccine (PPV). It was also agreed that, if the use of PPV is considered appropriate, PCV13 should be administered first, regardless of prior pneumococcal vaccination status.

Keywords: invasive pneumococcal disease (IPD), community-acquired pneumonia (CAP), Central and Eastern Europe (CEE), Israel, pneumococcal vaccines, vaccination, elderly adults

Received: September 17, 2013; Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Ludwig E, Ünal S, Bogdan M, Chlíbek R, Ivanov Y, Kozlov R, et al.. Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in Adults. Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults. Cent Eur J Public Health. 2013;21(4):233-236. doi: 10.21101/cejph.a3959. PubMed PMID: 24592732.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ludwig E, Ünal S, Bogdan M, Chlibek R, Ivanov Y, Kozlov R, et al. Opportunity for healthy ageing: lessening the burden of adult pneumococcal disease in Central and Eastern Europe, and Israel. Cent Eur J Public Health. 2012 Jun;20(2):121-5. Go to original source...
    2. Motlová J, Kozáková J, Křížová P. Invasive pneumococcal disease in the Czech Republic in 2010. Zpr Epid Mikrobiol. 2011;20(2):64-9. (In Czech.)
    3. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec. 2008 Oct 17;83(42):373-84. Go to PubMed...
    4. European Centre for Disease Prevention and Control (ECDC). Technical Report of the Scientific Panel on Vaccines and Immunisation. Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during an inter-pandemic period [Internet]. Stockholm: ECDC; 2007 [cited 2013 Nov 21]. Available from: http://ecdc.europa.eu/en/publications/Publications/0701_TER_Use_of_pneumococcal_polysaccharide_vaccine.pdf.
    5. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9. Go to original source...
    6. Imöhl M, Reinert RR, Mutscher C, van der Linden M. Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008. BMC Microbiol. 2010 Nov 25;10:299. Go to original source... Go to PubMed...
    7. Fenoll A, Aguilar L, Giménez MJ, Vicioso MD, Robledo O, Granizo JJ, et al. Variations in serotypes and susceptibility of adult non-invasive Streptococcus pneumoniae isolates between the periods before (May 2000-May 2001) and 10 years after (May 2010-May 2011) introduction of conjugate vaccines for child immunisation in Spain. Int J Antimicrob Agents. 2012 Jul;40(1):18-23. Go to original source... Go to PubMed...
    8. Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012 May;31(5):501-8. Go to original source... Go to PubMed...
    9. Motlová J, Beneš Č, Kozáková J, Křížová P. Invasive pneumococcal disease in the Czech Republic in 2011. Zpr Epid Mikrobiol. 2012;21(2):51-8. (In Czech.)
    10. Chilosi M, Poletti V, RossiA. The pathogenesis of COPD and IPF: distinct horns of the same devil? Respir Res. 2012 Jan 11;13:3. Go to original source... Go to PubMed...
    11. Moberley SA, Holden J, Tatham DP,Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000422. Go to original source... Go to PubMed...
    12. Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012 May 1;205(9):1408-16. Go to original source... Go to PubMed...
    13. HussA, Scott P, StuckAE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009 Jan 6;180(1):48-58. Go to original source... Go to PubMed...
    14. de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008 Apr 1;46(7):1015-23. Go to original source... Go to PubMed...
    15. Hammitt LL, Bruden DL, Butler JC, Baggett HC, Hurlburt DA, Reasonover A, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J Infect Dis. 2006 Jun 1;193(11):1487-94. Go to original source... Go to PubMed...
    16. French N, Gordon SB, MwalukomoT,White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIVinfected adults. N Engl J Med. 2010 Mar 4;362(9):812-22. Go to original source... Go to PubMed...
    17. Summary of product characteristics. Prevenar13 [Internet]. London: European MedicinesAgency; 2012 [cited 2013 Nov 21].Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.
    18. European MedicinesAgency. Prevenar 13: pneumococcal polysacharide conjugate vaccine (13-valent, adsorbed) [Internet]. European Medicines Agency; 2011 [cited 2013 Nov 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/001104/WC500112838.pdf.
    19. Schwarz TF, Flamaing J, Rümke HC, Penzes J, Juergens C, WenzA, et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine. 2011 Jul 18;29(32):5195-202. Go to original source... Go to PubMed...
    20. Frenck RWJr, GurtmanA, Rubino J, SmithW, van Cleeff M, Jayawardene D, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol. 2012 Aug;19(8):1296-303. Go to original source... Go to PubMed...
    21. Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine. 2013 Jan 2;31(2):291-4. Go to original source... Go to PubMed...
    22. Federal Ministry of Health. Austrian vaccination plan 2013 [Internet]. Vienna: Federal Ministry of Health; 2013 [cited 2013 Nov 21]. Available from: http://www.bmg.gv.at/cms/home/attachments/3/3/6/CH1100/CMS1327680589121/impfplan2013.pdf. (In German.)
    23. Ministry of Health and Social Welfare.Adult vaccination program [Internet].Athens: Ministry of Health and Social Welfare; 2011 [cited 2013 Nov 21].Avail¬able from: http://static.diavgeia.gov.gr/doc/45ΨΨΘ-2ΘΜ. (In Greek.)
    24. Regulation for the ammendment and extension to Regulation No 15 from 2005 on immunizations in the Republic of Bulgaria. Drzhaven Vestnik [Internet]. 2012 Oct 9 [cited 2013 Nov 21]:77. Available from: http://dv.parliament.bg/DVWeb/showMaterialDV.jsp?idMat=68970. (In Bulgarian.)
    25. Vaktsiin.ee.Adult vaccination calendar, Estonia [Internet]. Tallinn: Vaktsiin.ee; 2013 [cited 2013 Nov 21]. Available from: http://www.vaktsiin.ee/arstile/taiskasvanute-vaktsineerimiskalender/. (In Estonian.)
    26. Hungarian National Centre for Epidemiology. Vaccination guidelines 2012. Epinfo. 2012;19 Suppl 1:1-56. (In Hungarian.)
    27. Baltic Immunoprophylactic Association. Lithuanian vaccination recommendations 2012 [Internet]. Vilnius: BALTIPA; 2012 [cited 2013 Nov 21]. Available from: http://www.baltipa.lt/data/Skiepai_A5_24psl_SPAUDAI_2.pdf. (In Lithuanian)
    28. National Medicines Institute. Recommendations on the management of bacterial infections of the central nervous system [Internet]. Warsaw: National Medicines Institute; 2011 [cited 2013 Nov 21].Available from: http://www.koroun.edu.pl/pdf/rekomendacje-ukl-nerwowy_2011.pdf. (In Polish.)
    29. High Council of Public Health (HCSP). Opinion on the recommendations of vaccination for adults and children over 2 years at risk of invasive pneumococcal infection [Internet]. Paris: HCSP; 2013 [cited 2013 Nov 21].Available from: http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspa20130425_infectionsinvasivespneumocoque.pdf. (In French.)
    30. National Institute for Public Health and the Environment (RIVM). Guideline for prevention of infec¬tions in (functional) hypo- and asplenia [Internet]. Bilthoven: National Institute for Public Health and the Environment (RIVM); 2012 [cited 2013 Nov 21].Available from: http://www.rivm.nl/dsresource?objectid=rivmp:52820&type=org&disposition=inline&ns_nc=1. (In Dutch.)
    31. Government of Galicia, Ministry of Health. Instruction 012/2012: On the use of anti-pneumococcal thirteen-valent conjugate vaccine in persons 50 or more years of age belonging to risk groups [Internet]. Santiago de Compostela: Government of Galicia, Ministry of Health; 2012 [cited 2013 Nov 21]. Available from: http://www.sergas.es/gal/DocumentacionTecnica/docs/SaudePublica/vacunas/PNEUMO_conxugada_adultos_firmada.pdf. (In Galician.)
    32. Federal Ministry of Health (BAG); Federal Commission on Vaccination (EKIF). Recommendations for the vaccination of recipients of blood stem cells. Bull Bundesamt Gesundh [Internet]. 2012 [cited 2013 Nov 21];(21):363-70. Available from: http://www.bag.admin.ch/themen/medizin/00682/00684/02535/. (In German.)
    33. UK Department of Health. Pneumococcal the green book, chapter 25 [Internet].London:UKDepartmentofHealth;2013[cited2013Nov21].Available from: http://immunisation.dh.gov.uk/green-book-chapters/chapter-25/.
    34. Recommendations of the Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Update July 2012: Vaccination calendar. Epidemiologisches Bull. 2012;(30):284-5. (In German.)
    35. SkoczyńskaA, Sadowy E, Bojarska K, Strzelecki J, KuchA, Gołębiewska A, et al.; Participants of laboratory-based surveillance of community acquired invasive bacterial infections (BINet). The current status of invasive pneumococcal disease in Poland. Vaccine. 2011 Mar 3;29(11):2199-205. Accepted in November 3, 2013 Go to original source... Go to PubMed...

    Return to the content